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Background: Quantum dots are fluorescent nanoparticles with unique photophysical properties 
that allow them to be used as diagnostic, therapeutic, and theranostic agents, particularly in 
medical and surgical oncology. Near-infrared-emitting quantum dots can be visualized in deep 
tissues because the biological window is transparent to these wavelengths. Their small sizes and 
free surface reactive groups that can be conjugated to biomolecules make them ideal probes for 
in vivo cancer localization, targeted chemotherapy, and image-guided cancer surgery. The human 
epidermal growth factor receptor 2 gene (HER2/neu) is overexpressed in 25%–30% of breast 
cancers. The current methods of detection for HER2 status, including immunohistochemistry 
and fluorescence in situ hybridization, are used ex vivo and cannot be used in vivo. In this paper, 
we demonstrate the application of near-infrared-emitting quantum dots for HER2 localization 
in fixed and live cancer cells as a first step prior to their in vivo application.
Methods: Near-infrared-emitting quantum dots were characterized and their in vitro toxicity 
was established using three cancer cell lines, ie, HepG2, SK-BR-3 (HER2-overexpressing), 
and MCF7 (HER2-underexpressing). Mouse antihuman anti-HER2 monoclonal antibody was 
conjugated to the near-infrared-emitting quantum dots.
Results: In vitro toxicity studies showed biocompatibility of SK-BR-3 and MCF7 cell lines 
with near-infrared-emitting quantum dots at a concentration of 60 µg/mL after one hour and 
24 hours of exposure. Near-infrared-emitting quantum dot antiHER2-antibody bioconjugates 
successfully localized HER2 receptors on SK-BR-3 cells.
Conclusion: Near-infrared-emitting quantum dot bioconjugates can be used for rapid localiza-
tion of HER2 receptors and can potentially be used for targeted therapy as well as image-guided 
surgery.
Keywords: anti-HER2 antibody, HER2 localization, quantum dots, in vitro imaging, nano-
technology, cancer
Introduction
Among the many potential applications of nanotechnology in medicine, cancer diag-
nosis and therapy remains the most significant and has led to the development of a 
new discipline of nano-oncology.1–13 Nanoparticles or nanomaterials can be broadly 
classified as organic and inorganic. Organic nanoparticles include nanoliposomes, 
dendrimers, amphiphilic block copolymer micelles, and carbon nanotubes. Inorganic 
nanoparticles can be metallic (eg, gold, silver, superparamagnetic iron oxide) or com-
posed of semiconductor material, eg, quantum dots (QDs). Each type of nanoparticle 
has unique characteristics based on its composition, size, and surface chemistry, 
that determine its stability, biocompatibility, and interaction with the surrounding 
environment. Nanoparticles are actively being developed as probes for in vivo tumor 
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 targeting, biomolecular profiling of cancers, nanovectors for 
drug delivery, and various theranostic applications.2,4
Of all the different types of nanoparticles, semiconduc-
tor nanocrystals, or QDs, have gained significant attention 
due to their unique photophysical properties as the next-
generation fluorophores. QDs are fluorescent 2–10 nm 
nanocrystals that can be used as alternative probes for a 
host of diagnostic, therapeutic, and theranostic applications 
in medical and surgical oncology.14 Their broad absorption 
and narrow symmetric emission spectra, large molar extinc-
tion coefficients, high quantum yield, and enhanced photo-
stability give them tremendous advantages over traditional 
 fluorophores for biomolecular and cellular imaging in vitro 
and in vivo.15 QDs can be size-tuned to emit at near-infrared 
(NIR, 650–1,000 nm) wavelengths, which are ideal for deep 
tissue imaging because the biological window is transparent 
to these wavelengths. This is based on the fact that tissue 
chromophores like hemoglobin absorb light in the visible 
spectrum (400–700 nm), leading to scattering, diffraction, 
and poor penetration through the skin. Light in the NIR 
range does not undergo this absorption and scattering effect, 
allowing deeper penetration and visibility.16–20 Multiple QDs 
of different colors can be excited by a single wavelength 
of light, a concept of multiplexed imaging that is a certain 
advantage in biological imaging where multiple targets can 
be detected at a single point in time. Also, their small size 
and free surface reactive groups allow conjugation to various 
biomolecules for targeted localization, making them potential 
candidates for various applications, like cancer localization, 
detection of micrometastasis, image-guided drug delivery, 
and image-guided cancer surgery.16,20–28
The human epidermal growth factor receptor 2 gene 
ErbB2 (commonly referred to as HER2/neu) is a v-erb-b2 
erythroblastic leukemia viral oncogene homolog 2 gene29 
that may be overexpressed in a number of cancers, including 
breast, colorectal, non-small-cell lung, and head and neck 
cancer.30–32 The gene encodes a member of the epidermal 
growth factor (EGF) family of transmembrane receptors 
with tyrosine kinase activity, including EGFR (also called 
HER1 or ErbB1), HER2 (ErbB2 or neu), HER3 (ErbB3), 
and HER4 (ErbB4). The HER2/neu gene is overexpressed in 
25%–30% of breast cancers,33,34 and the primary mechanism 
of overexpression is amplification, which leads to increased 
tyrosine kinase activity and dysregulated growth of cells. 
The significance of determining HER2 status in breast can-
cer treatment relates to the fact that HER2-positive tumors 
are associated with higher aggressiveness, recurrence, and 
increased mortality among newly diagnosed cases that do 
not receive systemic chemotherapy.29 Hence targeting and 
blocking the HER2 receptor using a humanized monoclonal 
antibody called trastuzumab (Herceptin®; Genentech Inc, 
South San Francisco, CA, USA) leads to improved response 
rates and delays the time to disease progression, and hence 
prolongs survival either alone or in combination with other 
chemotherapies in metastatic disease.35 However, the use of 
trastuzumab is associated with a risk of cardiotoxicity36,37 and 
this, coupled with the high costs of the drug and therapies 
of up to 9–12 months, demands that HER2 testing has high 
sensitivity to identify all patients with HER2 positivity as 
well as high specificity to detect all the negative patients 
who would not benefit from the therapy and hence not suffer 
the side effects.29
The current methods for detecting HER2 status include 
immunohistochemistry and fluorescence in situ hybridiza-
tion (FISH), and both have problems based on variability 
and consistency of results.29,38 Immunohistochemistry is 
used to detect protein expression and FISH to detect gene 
amplification. The disadvantages of immunohistochemistry 
include it being prone to interference factors, having unstable 
sensitivity, and showing a high discrepancy between labora-
tories; further, it has a subjective interpretation and is a semi-
quantitative technique. FISH, on the other hand, although 
highly sensitive, is complex, expensive, labor-intensive, 
time-consuming, and requires special equipment, including 
manual expertise.29,39–42 The FISH assay is technically more 
reproducible and is currently considered the “gold standard” 
for HER2 testing. However, it may cause difficulty in assess-
ment of the morphological features of the tumor along with 
decay in the fluorescence signal, which leads to loss of results 
after a few weeks. To overcome these problems, chromogen 
in situ hybridization has been used as an alternative method 
because its signals are permanent and samples can be assessed 
in the light of morphological features.43 However, there are 
mixed reports regarding the sensitivity of chromogen in situ 
hybridization in comparison with FISH, particularly in low 
amplification tumors.43–45 Also, all the above methods can be 
used for ex vivo detection of HER2 status, and to date there 
is no means of detecting HER2 status in vivo.
NIR-emitting QDs (NIR-QDs) have been investigated as 
promising probes for in vitro and in vivo imaging.19,24 The 
potential application of QDs as molecular probes for the 
detection of breast cancer has already been described.38,46–50 
Many researchers have suggested the application of QDs as 
fluorescent probes for immunohistochemistry based on their 
advantages over traditional fluorophores38,46–48 Chen et al 
demonstrated that QD immunohistochemistry can be used 
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for quantitative determination of the HER2 load which may 
better reveal breast cancer heterogeneity.49 In another study, 
the same group looked at simultaneous detection of HER2 
and the estrogen receptor in breast cancer using QD immuno-
histochemistry, and showed that multiplexed imaging of the 
HER2 and estrogen receptor would enhance the understand-
ing of their interaction during evolution of breast cancer.51 In a 
similar context, Liu et al used QD-based multiplexed imaging 
to demonstrate that high HER2 expression is associated with 
increased destruction of the extracellular matrix and vascular 
invasion of breast cancer.52 In this study, we explored direct 
conjugation of the anti-HER2 antibody with the QD surface 
using carbodiimide surface chemistry for direct detection of 
HER2 receptors without the need for a secondary antibody, 
as is required for immunohistochemistry. We have previously 
reported the aqueous synthesis of a core/shell/shell QD based 
on CdTe/CdSe/ZnSe coated with mercaptoundecanoic acid 
(MUA) as an NIR probe for deep tissue imaging.53 Here 
we have demonstrated the localization of HER2 receptors 
in both fixed and live cells, examined two protocols of QD 
bioconjugation, and also evaluated the in vitro toxicity of 
QDs as a first step towards their eventual application for in 
vivo imaging.
Materials and methods
Materials
McCoy’s 5A (modified) Medium was obtained from the 
 American Type Culture Collection (Manassas, VA, USA); 
a penicillin-streptomycin mixture, trypsin/ethylenediamine 
 tetraacetic acid, phosphate-buffered saline (without Ca2+, 
Mg2+, or phenol red), and Dulbecco’s Modified Eagle Medium 
(DMEM) and F12 in a 1:1 mixture with HEPES and L- glutamate 
was sourced from Lonza (Walkersville, MD, USA); DMEM and 
mouse antihuman unconjugated monoclonal antibody erbB-2 
(HER2) was sourced from Invitrogen  (Carlsbad, CA, USA); fetal 
bovine serum, Tween 20, N-ethyl-N’-(3- dimethylaminopropyl)
carbodiimide (EDC) $98.0% was purchased from Fluka (St 
Louis, MO, USA); and N- hydroxysuccinimide (NHS) 98% was 
obtained from Sigma-Aldrich (St Louis, MO, USA). A Cell 
Titer-Blue® cell viability assay was obtained from Promega 
(Madison, WI, USA). CdTe/CdSe/ZnSe quantum dots coated 
with MUA were synthesized in the laboratory according to our 
published protocols.53
Methods
Preparation of QDs
Core/shell/shell CdTe/CdSe/ZnSe QDs were aqueously 
synthesized by a previously described one pot method.53 
The QDs had an MUA coating and were soluble in aqueous 
medium. After synthesis, the QDs were purified by addition of 
 isopropanol/butanol (1:1) mixture followed by centrifugation 
and redispersion in deionized water or phosphate-buffered 
saline. The QD concentration was calculated by assessment 
of the dry weight of QDs per mL of growth  solution. We 
noticed that, after vacuum-drying, the QDs could not be 
redispersed in water. Therefore, after centrifugation, the 
wet pellet was dispersed in phosphate-buffered saline and, 
based on calculations from the amount of dry QDs per mL 
of growth solution, QD concentrations were prepared for 
the in vitro cytotoxicity assessments. The concentration of 
elemental cadmium was calculated using inductively coupled 
plasma mass spectrometry.
characterization
Absorption spectroscopy measurements were taken using a 
U-4100 ultraviolet-visible NIR spectrophotometer (Hitachi 
Ltd, Tokyo, Japan) over a wavelength of 300–1,100 nm. The 
samples were measured in a quartz cuvette with a 1 cm path 
length and using an aqueous solvent (deionized water or 
phosphate-buffered saline) as a reference. Photoluminescence 
spectra were obtained using an LS 50B spectrometer 
(PerkinElmer, Boston, MA, USA) in the same cuvette as 
absorption spectroscopy (excitation wavelength being 400 
nm). The diameter of the QD cores was assessed using a 
Tecnai™ 20 transmission electron microscope (FEI Co, Hill-
boro, OR, USA) with an acceleration voltage of 200 kV for 
normal and high resolution images. Samples were dropped 
onto a copper grid with an amorphous carbon film and left 
to evaporate under ambient conditions. Dynamic light scat-
tering studies were performed to establish the hydrodynamic 
diameter of the MUA-coated QDs using a Delsa™ nano 
submicron particle size and zeta potential particle analyzer 
(Beckman Coulter Inc, Pasadena, CA, USA). All samples 
were thoroughly sonicated at 37°C for 15 minutes prior to 
measurements. A FT/IR 6300 Fourier transform infrared 
(FTIR) spectroscope (Jasco Analytical Instruments, Easton, 
MD, USA) with an MCT detector was used for FTIR analysis 
with phosphate-buffered saline as a background reference. 
FTIR of the MUA powder was done to demonstrate attach-
ment of MUA to the QD surface. A few drops of unconjugated 
and conjugated QDs were placed separately on the ATR prism 
and spectra were obtained in solution.
cell culture
SK-BR-3 cells (a human breast adenocarcinoma cell line 
overexpressing HER2) were obtained and cultured in 
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McCoy’s 5A Medium with 10% fetal bovine serum and 1% 
penicillin/streptomycin formulated by the American Type 
Culture Collection. MCF7 cells (a human breast ductal carci-
noma cell line not overexpressing HER2) were sourced from 
the European Collection of Cell Cultures (Salisbury, UK) and 
cultured in DMEM:F12 in a 1:1 mixture (with HEPES and 
L-glutamine) and 10% fetal bovine serum and 1% penicillin/
streptomycin. HepG2 cells were supplied at passage number 
50 from the Liver Group at the Centre for Hepatology, Depart-
ment of Medicine, Royal Free Hospital and Medical School, 
University College London. Once received, the medium was 
changed to DMEM (+4.5 g/L glucose) and supplemented 
with fetal bovine serum 10% and penicillin/streptomycin 
1%, which was then replaced a few times over a period of a 
week to 10 days. All cells were cultured and passaged in 75 
cm² cell culture flasks up to 90% confluence with complete 
cell culture medium (CCM) in a humidified chamber at 37°C 
with 5% CO
2
. The CCM was changed every 2–3 days and 
both cell lines were used at passage 4 and 5.
The methodology for testing of in vitro cytotoxicity was 
established using the Cell Titre Blue assay. To establish the 
best seeding density for in vitro cytotoxicity in a 96-well 
plate, SK-BR-3, MCF7, and HepG2 cells were laid down at 
densities of 40 × 103, 20 × 103, 10 × 103, 5 × 103, and 2.5 × 103 
cells in 100 µL of CCM per well. The cells were incubated in 
a humidified chamber at 37°C with 5% CO
2
 overnight, fol-
lowing which the CCM was removed, the cells were washed 
with phosphate-buffered saline, and fresh CCM was replaced. 
Next, 20 µL of Cell Titre Blue assay was added to each 
well and the plates were incubated in a humidified chamber 
at 37°C with 5% CO
2
 for 4 hours. The fluorescence of the 
96-well plates was read using a Fluoroskan Ascent microplate 
fluorometer (Thermo Scientific, Baltimore, MD, USA). The 
fluorescence was measured with excitation at 530 nm and 
emission at 620 nm. For both SK-BR-3 and MCF7 cells, the 
best seeding density in a 96-well plate was 20,000 cells per 
well and for HepG2 was 40,000 cells per well.
In vitro cytotoxicity
For in vitro toxicity, the cells were seeded in 96-well plates 
at the established density of 20,000–40,000 cells per well 
in 100 µL of CCM and incubated overnight in a humidified 
chamber at 37°C with 5% CO
2
. Following this, the CCM was 
removed, the cells were washed with phosphate-buffered 
saline and then exposed to variable concentrations of QDs 
(1.25–60 µg/mL) in CCM, where the volume of CCM was 
kept constant and the concentrations of QDs were altered 
using variable volumes of phosphate-buffered saline. The 
plates were incubated in a humidified chamber at 37°C 
with 5% CO
2
 for one hour and 24 hours. After the desired 
exposure times, the CCM with QDs was removed and 
replaced with fresh CCM after washing the cells twice with 
phosphate-buffered saline. Next, 20 µL of Cell Titre Blue 
assay was added to each well, the plates were incubated in a 
humidified chamber at 37°C with 5% CO
2
 for 4 hours, and 
cell viability was established by determining fluorescence 
using the Fluoroskan Ascent microplate fluorometer filter 
sets for excitation (Ex) and emission (Em) 530
Ex
/620
Em
. QD 
concentrations alone without cells were also read by the 
plate reader to establish that the fluorescence measurements 
represented cell viability and not QD fluorescence. For 
comparison, all cell viability (CV) data were presented as 
the percentage of treated cells (exposed to QDs) to untreated 
cells (not exposed to QDs), which was calculated using the 
following formula:
 CV
Ft
Fc
(%) = 

 × 100
where Ft represents the fluorescence reading for treated cells 
and Fc represents the fluorescence reading for untreated 
cells in the cell viability assay. All assays were performed 
in triplicate and the results averaged.
In vitro imaging
For assessing the morphology of the cells after QD exposure, 
both cell types were cultured in glass-bottomed 96-well 
plates. After QD exposure for one hour and 24 hours, the 
cells were washed with phosphate-buffered saline and fixed 
with glutaraldehyde before imaging with a light microscope. 
An EC-1 confocal microscope from Nikon (Tokyo, Japan) 
was used to assess fluorescence.
Bioconjugation of QDs
A solution of QDs with a concentration of 0.5 mg/mL was 
prepared in phosphate-buffered saline and the anti-HER2 
antibody was diluted in phosphate-buffered saline to a 
concentration of 100 µg/mL. Two different protocols were 
examined for bioconjugation based on the use of both EDC 
and NHS or EDC alone for activation of the QDs. For the 
first protocol, 1 mg of EDC powder and 1 mg of NHS powder 
were added to 0.5 mL of 0.5 mg/mL CdTe/CdSe/ZnSe-MUA 
QDs. For the second protocol, only 1 mg of EDC powder 
was added to the same concentration of QDs. To activate the 
QDs, the materials were incubated at room temperature in an 
orbital rotator for 40 minutes. After the activating process, 
International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1327
Near-infrared QDs for her2 localization
all of the antibody solution (100 µg/mL) was added and left 
for one hour at room temperature on the orbital rotator, fol-
lowing which it was purified by centrifugal filtration using an 
Amicon Ultra-0.5 centrifugal filter unit with an Ultracel-30 
membrane (Millipore, Billerica, MA, USA) for 10 minutes at 
a speed of 10 g. This removed all the unconjugated QDs and 
unreacted materials as a filtrate. The antibody-QD conjugate 
retained by the filtration membrane was diluted 50 times in 
phosphate-buffered saline and characterized using FTIR to 
confirm bioconjugation. Figure 1 is a schematic diagram that 
demonstrates the methodology used for bioconjugation and 
targeted localization of the surface receptors.
her2 localization using the QD-antibody  
bioconjugate
SK-BR-3 cells and MCF7 cells were cultured on glass cham-
ber slides in McCoy’s 5A Medium and DMEM:F12 with 10% 
fetal bovine serum and 5% penicillin/streptomycin overnight. 
When they reached approximately 80% confluence, the CCM 
was removed and the cells were washed thoroughly with 
phosphate-buffered saline and fixed with glutaraldehyde. For 
live cell imaging, each chamber was washed and replenished 
with 1 mL of fresh CCM. Next, 1 mL of QD-antibody con-
jugate prepared using EDC/NHS or EDC alone was added to 
each chamber of fixed and live cells. The treated plates were 
placed on a gentle shaker for one hour at room temperature, 
following which the QD-antibody solution was removed and 
the cells were washed thoroughly with 0.05% phosphate-
buffered saline and Tween 20 for 10 minutes to remove all 
unbound QD-antibody conjugates. The slides were visualized 
using an EC1 confocal microscope from Nikon.
statistical analysis
The statistical analysis was performed using the Prism software 
and nonparametric one-way analysis of variance with Dunnett’s 
and Bonferroni multiple comparisons test. A P-value ,0.05 
was considered to be statistically significant.
Results
QD characterization
The QDs demonstrated an absorption onset (700 nm) and 
emission peak (720 nm) in the NIR range (Figure 2A). 
Transmission electron microscopy showed that the QDs 
were mostly spherical in shape with a core diameter of 
4±0.8nm (Figure 2B). Dynamic light scattering studies 
showed that MUA-coated QDs had a hydrodynamic diameter 
of 19.8±5 nm. FTIR confirmed the presence of the MUA 
 coating, showing peaks at 998 cm−1 from O–H bending of the 
Anti-HER2-AbMUA-coated QD
EDC/NHS
Coupling reaction
QD-Anti-HER2-Ab conjugate
QD-Anti-HER2-Ab
conjugate
binds to HER2
receptors
SKBR3 cell
HO
HO
HO
HO
HOHO
OH OH
OH
OH
OH
OH
O
O
O
O
O
O
O
O
O
O
O
O
NH2
NH2 NH2
NH2 NH2
NH2
NH2
NH2
NH2
NH2
+
Figure 1 Methodology of bioconjugation of mercaptoundecanoic acid-coated QDs and application for localization of her2 receptors. anti-her2-ab conjugates to the QD 
surface through an amide linkage. The QD-anti-her-ab conjugate then targets and localizes to the her2 receptors overexpressed on sK-Br-3 cells.
Abbreviations: ab, antibody; her2, human epidermal growth factor receptor 2; QD, quantum dot.
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carboxylic acid, as well as peaks at 1,259 cm−1 and 1,742 cm−1 
from stretching of C−O and C=O groups respectively, show-
ing that the MUA had bonded to the QD surface (Figure 6A). 
The dry weight of QDs in the growth solution was 0.4 mg/mL 
and this equaled an elemental cadmium concentration of 
148 µg/mL by inductively coupled plasma mass spectrometry. 
The molar concentration of QDs calculated based on Beer 
Lamberts Law was 8.08 µM.
In vitro cytotoxicity
There was no significant difference in the viability of MCF7 
cells on exposure to a QD concentration of up to 60 µg/mL for 
one hour and 24 hours compared with the control group. The 
cell viabilities at 24 hours appeared marginally lower when 
compared with the one-hour samples for QD  concentrations 
at 1.25–10 µg/mL and 60 µg/mL. However, this was not 
statistically significant. Similarly, there was no evidence of 
a significant decrease in viability of SK-BR-3 cells at any 
concentration (0–60 µg/mL) at one hour and 24 hours of 
exposure (Figure 3). HepG2 cells did not show any signifi-
cant difference in cell viability compared with the control 
at one hour. However, at 24 hours, there was a significant 
concentration-dependent decrease in cell viability evident 
at 15, 30, and 60 µg/mL (P,0.05, P,0.01, and P,0.01, 
respectively). In comparison with one hour, the cell viability 
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Figure 3 In vitro cytotoxicity of cdTe/cdse/Znse mercaptoundecanoic acid-coated 
QDs in McF7, sK-Br-3, and hepg2 cells.
Notes: (A and B) MCF7 and SK-BR-3 cells show no evidence of significantly reduced 
viability at one hour and 24 hours. (C) HepG2 cells show significantly decreased cell 
viability at $15 µg/ml by 24 hours. *P,0.05; **P,0.001.
Abbreviation: QDs, quantum dots.
0.0 0
10
20
30
40
50
60
70
80
300 400 500
Wavelength/nm
600 700 800
0.2
0.4
0.6
0.8
1.0
1.2
A
b
so
rb
an
ce
/a
rb
it
ra
ry
 u
n
it
In
te
n
si
ty
/a
rb
it
ra
ry
 u
n
it
1.4
1.6
1.8
2.0
2.2
A
B
PL and Abs spectra of CdTe/CdSe/ZnSe QDs
λex=550 nm
Figure 2 characterization of the QDs.
Notes: (A) abs and Pl emission spectra for cdTe/cdse/Znse mercaptoundecanoic 
acid-coated QDs excited by light of wavelength (λex) 550 nm. (B) Transmission 
electron micrograph showing a core diameter of 4±0.8 nm.
Abbreviations: abs, absorption; Pl, photoluminescence; QDs, quantum dots.
International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1329
Near-infrared QDs for her2 localization
decreased significantly to #75% at 30 µg/mL and ,50% at 
60 µg/mL (P,0.05 and P,0.001, respectively).
cell morphology
There was no evidence of changes in cellular morphology 
and architecture in MCF7 (Figure 4A–C) and SK-BR-3 cells 
 (Figure 4D–F) at one hour and 24 hours when compared 
with the control group. However, HepG2 cells (Figure 4G–I) 
showed evidence of cellular breakdown and loss of polygonal 
architecture, with reduced cell density at 24 hours of exposure 
at higher concentrations of 30–60 µg/mL in comparison with 
the control group. On a one-hour exposure, HepG2 cells showed 
no evidence of any morphological changes (Figure 4H).
Bioconjugation of QDs
The EDC and NHS powder readily dissolved in 1 mL of 
0.5 mg/mL QD solution. EDC is a water-soluble carbodi-
imide used for immunoconjugate preparations, crosslinking 
of protein to nucleic acids, and peptide synthesis (Figure 5). 
It is used for activating the carboxylic end of the amino acid 
for the coupling of primary amines to form an amide bond. 
NHS is used as a catalyst to increase the efficiency of the 
coupling reaction. While a reaction with amines and a normal 
carboxylic acid would just make a salt, activation by NHS 
would prime the acid to make an amide bond.
After activation, 1 mL of antibody solution (100 µg/mL) 
was added to the activated QDs and the solution was left at room 
temperature for one hour. The QDs glowed a deep red on ultra-
violet excitation, confirming that fluorescence was not quenched 
during the bioconjugation process. Centrifugal  filtration was 
used to remove any unbound QDs, as the filtration membrane 
had a cutoff of 30 kDa and the size of the antibody was 185 kDa. 
Because only a very small amount of antibody was added 
(10 µg) with an excess of QDs (500 µg), we assumed that 
all the antibody would conjugate to the QDs and any excess 
unbound QDs would pass out through the filtration membrane. 
I
A
D
G H I
E F
B C
MCF7
SK-BR-3
HepG2
II III
Figure 4 light microscopy images of McF7 (A–C) sK-Br-3 (D–F), and hepg2 (G–I) cells exposed to 60 µg/ml of QDs for one hour and 24 hours. column I shows the 
control cells; column II shows cells after one hour of exposure; and column III shows cells after 24 hours of exposure. (B and C) McF7 cells and (E and F) sK-Br-3 cells 
show no change in cell morphology or cell numbers at either time point. (H and I) hepg2 cells show no evidence of change in cell morphology at one hour (G) but there is 
evidence of cellular breakdown with loss of polygonal architecture at 24 hours (I).
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After filtration, the centrifugate of the sample (EDC + NHS) 
retained by the filtration membrane glowed a deep red, with 
minimal or no fluorescence in the filtrate, indicating that all 
the QDs had conjugated to the antibody. However, the EDC-
only sample showed evidence of minimal fluorescence in the 
centrifugate, indicating that the majority of the QDs were not 
bound and the coupling reaction was inefficient.
characterization of QD-antibody 
bioconjugate
FTIR was used to confirm the efficiency of the cou-
pling  reaction. Three samples were analyzed, including 
 QD-antibody conjugated by the EDC/NHS coupling method, 
anti-HER2 antibody, and CdTe/CdSe/ZnSe MUA QDs alone. 
The sample of QD conjugated to the antibody using EDC did 
not show any prominent peaks and is therefore not shown. 
The graphs were overlaid to compare the absorption peaks 
(Figure 6B). There were four significant peaks in the QD-
antibody conjugated using the EDC/NHS coupling method 
that were not detected in the other samples. The peak at 
1,707.66 cm−1 corresponds to the C=O stretching from car-
boxylic acid on the QDs. In the QD sample, the C=O peak 
occurs at 1,742 cm−1 and a shift to a lower wave number of 
1,707.66 cm−¹ may correspond to QD conjugation with the 
antibody. The second peak at 1,637.27 cm−1 corresponds to 
stretching vibrations in C=O and C−N from an amide I linkage. 
The prominent peak at 1,569.66 cm−1 was closest to amide II 
and corresponded to NH bending and stretching vibrations 
from C−N. The infrared absorption peak at 1,235.18 cm−1 
was close to amide III (1,200–1,305 cm−1) and was related 
to CN stretching and NH bending. Amide III is a complex 
band dependent on the details of the force field, nature of the 
side chains, and hydrogen bonding. The antibody on its own 
showed prominent peaks at 1,643 cm−1 and 1,516 cm−1, rep-
resenting amide I and amide II bonds. The shift in the peak at 
1,516 cm−1 to 1,569 cm−1 may indicate  bioconjugation. Also, 
the prominent peak at 998 cm−1 from the O–H groups on the 
MUA disappeared, indicating formation of an amide link. 
The FTIR results showed carbodiimide-activated coupling 
between the amine groups on the antibody and the carboxylic 
QD
QD
Amide bond
NHS Stable NHS ester
QD
QD
OH
OH
Amide bond
O
O
O
O
+
+
H
N
H
N
Ab
Ab
Ab
Ab
Hydrolysis
H2N
H2N
+ EDC
O-acylisourea ester
unstable
Figure 5 carbodiimide-based coupling reaction. The -cOOh groups of mercaptoundecanoic acid on the QD surface are activated by eDc to form an unstable intermediate 
O-acylisourea which may react with the Nh2 groups on the ab to form an amide bond or rapidly hydrolyze to yield -cOOh groups. addition of Nhs yields a stable reactive 
Nhs ester intermediate that reacts with Nh2 groups on the ab to yield a stable amide bond.
Abbreviations: ab, antibody; eDc, N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide; Nhs, N-hydroxysuccinimide; QD, quantum dot.
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groups on the QD. This was not observed for the EDC-only 
sample. The QDs were still glowing a deep red on ultraviolet 
excitation after the conjugation reaction.
Detection of cancer marker her2 with 
QD-anti-her2-antibody conjugate
The QD-anti-HER2-antibody conjugate was used to localize 
HER2 receptors on two breast cancer cell lines, including 
SK-BR-3 cells which overexpress HER2 receptors and MCF7 
cells that do not (negative control). Both fixed cells (Figure 7) 
and live cells (Figure 8) were exposed to the QD-anti-HER2-
antibody conjugate for a period of one hour. Confocal laser 
scanning microscopy images were taken and compared. The 
blue color shows the cell autofluorescence and the red color 
shows the QDs. Only cell autofluorescence was seen in the 
confocal images of unexposed SK-BR-3 and MCF7 cells. 
Fixed SK-BR-3 cells exposed to QD-anti-HER2-antibody 
(EDC and NHS) clearly showed evidence of fluorescence 
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Figure 6 Fourier transform infrared spectra of (A) cdTe/cdse/Znse MUa QDs (red) compared with MUa (black); (B) anti-her2-antibody (red) compared with bioconjugated 
QD-antibody (black).
Notes: (A) The MUa peak at 933 cm−1 from the O−h groups on the acid shifts to 998 cm−1 when MUa binds to the QD, indicating O−h bending. (B) The antibody alone 
shows prominent peaks at 1,643 cm−1 from amide I and 1,516 cm−1 from amide II. The peak at 1,516 cm−1 shifts to 1,569 cm−1 on the bioconjugated QD, showing stretching of 
the c–N and Nh2 groups. a new peak at 1,235 cm−1 may represent amide III linkage. The peak at 1,707 cm−1 may occur from stretching of the c=O bond on the MUa after 
bioconjugation. The prominent O–h peak at 998 cm−1 disappears in the bioconjugate, indicating formation of the amide bond.
Abbreviations: MUa, mercaptoundecanoic acid; QDs, quantum dots; her2, human epidermal growth factor receptor 2.
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A
D
B
E
C
SK-BR-3
MCF7
Figure 7 Fixed cell imaging of her2 receptors in sK-Br-3 (A–C) and McF7 (D and E) cell lines. (A) control sK-Br-3 and (B) sK-Br-3 cells exposed to QD-anti-her2-
antibody. (C) Magnified inset of (B) showing ring-like fluorescence of QDs on the cell surface. (D) control McF7 and (E) McF7 exposed to the QD-antiher2-antibody 
bioconjugate.
Note: HER2-overexpressing cells show significantly higher fluorescence as the QD-antibody probe binds to the cell surface (B). Arrow demonstrates magnified inset of 
image B in image C. In contrast, MCF7 have lower expression of HER2 and show minimal fluorescence.
Abbreviations: her2, human epidermal growth factor receptor 2; QDs, quantum dots.
SK-BR-3
A
D
B
E
C
MCF7
Figure 8 live cell imaging of sK-Br-3 (A–C) and McF7 (D and E) cells with the QD-anti-her2-antibody probe. (A) control sK-Br-3 cells. (B) Significantly higher uptake 
of QD-antibody bioconjugate by her2-overexpressing cells. (C) sK-Br-3 cells stained with the nuclear stain diamidino-2-phenylindole (DaPI) show localization of the QDs 
to the perinuclear region on live cell imaging (D) McF7 control and (E) McF7 cells show lower uptake of the QD-antibody probe because of their lower expression of the 
her2 receptor.
Abbreviations: her2, human epidermal growth factor receptor 2; QD, quantum dot.
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as small red dots on the cell surface, unlike the MCF7 cells, 
that did not show this pattern, with only occasional sites of 
nonspecific uptake (Figure 7). When live cells were exposed 
to the QD-anti-HER2-antibody conjugate (EDC and NHS), 
the SK-BR-3 cells clearly showed evidence of intracellular 
uptake with marked red fluorescence, unlike MCF7 cells, that 
showed a significantly lower uptake due to reduced expres-
sion of HER2 receptors (Figure 8). Two different protocols of 
QD conjugation were compared for both fixed and live cells. 
We found that QDs activated by EDC alone showed minimal 
HER2 localization because the efficiency of the reaction 
was low compared with use of EDC and NHS. This may be 
due to the instability of the bioconjugation intermediate at 
physiological pH when EDC is used on its own.
Discussion
In this study, we established the application of aqueously syn-
thesized NIR-QDs based on CdTe/CdSe/ZnSe for  localization 
of HER2 receptors in vitro for both fixed and live cells. The 
NIR-QDs were coated with MUA and showed an absorption 
onset and emission in the NIR range (Figure 2A). This means 
that, on in vivo injection, NIR light could be used to penetrate 
tissues to excite QDs which emitted at a slightly shifted 
NIR wavelength and could be detected by an NIR-sensitive 
 camera. Characterization of the QDs by transmission electron 
microscopy showed that they were approximately spherical 
in shape with a diameter of 4±0.8 nm (Figure 2B). FTIR 
analysis of the QDs compared with the spectra from MUA 
alone confirmed the presence of an MUA coating on the 
QD surface through a visible shift in the peak at 933 cm−1 
on MUA to 998 cm−1 from O–H bending of carboxylic acid 
when immobilized on the QD surface. The carbonyl peak 
at 1,692 cm−1 in the MUA also shifted to 1,742 cm−1 on the 
MUA coated QDs (Figure 6).
The main limitation to biomedical application of QDs is 
their toxicity, given that most QDs are based on heavy metals 
including cadmium, tellurium, and selenium. QD toxicity has 
been attributed to a range of factors, including surface coat-
ing, charge, chemistry, size, and mechanical and photochemi-
cal stability in the physiological environment.54 While some 
studies have shown the biocompatibility of QDs,55–57 others 
have demonstrated evidence of in vitro toxicity at concentra-
tions as low as 10 µg/mL.58–63 We examined the toxicity of 
MUA-QDs in three different cell lines, including SK-BR-3, 
MCF7, and HepG2, and found that the QDs at concentra-
tions of 60 µg/mL were biocompatible with SK-BR-3 and 
MCF7 cell lines at one hour and 24 hours. However, HepG2 
cells showed evidence of toxicity at QD  concentrations 
$15 µg/mL at 24 hours (Figure 3). This demonstrates a 
differential toxicity of QDs in different cell lines and may 
suggest different effects at the tissue and organ levels. It 
is likely that because the liver is a key site of metabolism, 
QDs are exposed to metabolic degradation after uptake by 
hepatocytes, leading to release of their toxic core components 
and reactive oxygen species. Therefore, hepatotoxicity is a 
considerable concern given that most in vivo studies demon-
strate maximum uptake by organs of the reticuloendothelial 
system, including the liver, spleen, lymph nodes, and bone 
marrow.64–67 However, various in vivo studies report that the 
time to maximum uptake by the liver is 4–6 hours, allowing 
enough time for an actively targeted probe to home in to its 
molecular destination.68–71
While the toxicity of QDs is a definite concern for various 
biological applications, cancer therapy is one area where this 
toxicity may be utilized to aid killing cancer cells. For exam-
ple, QDs can potentially be used as agents for photodynamic 
therapy in the management of cancer, when conjugated with 
photoactive dyes that can be activated with light to generate 
free radicals leading to localized cell death.15  Bioconjugated 
targeted NIR-QDs visible in deep tissues would be ideal for 
this purpose because they would accumulate at the site of the 
cancer which can then be ablated by light activation under 
image guidance.
Carbodiimide chemistry is commonly used to conjugate 
proteins. Figure 5 shows a schematic diagram explaining the 
coupling reaction between MUA-QDs and the anti-HER2 
antibody. A carbodiimide compound facilitates the direct 
conjugation of -COOH groups with primary amines. EDC 
is a zero-length crosslinker because it does not become part 
of the final crosslink between molecules. Also, because 
proteins and peptides contain both carboxyl and amino 
groups, direct EDC-mediated crosslinking may cause ran-
dom polymerization of the polypeptides. EDC activates the 
carboxyl group on the MUA to form an active O-acylisourea 
intermediate that reacts with the amine on the protein which 
forms an amide bond with the -COOH and an EDC byprod-
uct is released as a soluble urea derivative. However, the 
O-acylisourea intermediate is unstable in aqueous solution, 
and failure to react with an amine results in hydrolysis of 
the intermediate and regeneration of the carboxyl group. 
EDC crosslinking is most efficient at an acidic pH, and 
while a physiological pH is compatible with the reaction, 
the coupling efficiency is lower and requires a higher EDC 
concentration. NHS, or its water-soluble analog (Sulfo-NHS) 
is often included in EDC coupling protocols to improve 
efficiency. EDC couples NHS to carboxylic groups,  resulting 
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in  formation of an NHS ester that is considerably more 
stable than the O-acylisourea intermediate while allowing 
for efficient conjugation to primary amines at physiological 
pH. Hence, in summary, EDC reacts with a carboxyl group 
on the MUA-QD to form an amine-reactive O-acylisourea 
intermediate. However, this intermediate is unstable, and 
may either react with an amine on the antibody to yield a 
bioconjugate joined by a stable amide bond or may hydrolyze 
in aqueous solution to reform the -COOH group. Given that 
the efficiency of the reaction is low at physiological pH, 
addition of NHS stabilizes the amine-reactive intermediate 
by converting it to an amine-reactive NHS ester which then 
reacts with the amine group on the antibody to yield a stable 
amide bond along with increasing the efficiency of the EDC-
mediated coupling reaction.72,73
The QD-antibody conjugate was characterized by FTIR 
and showed successful conjugation in the EDC/NHS medi-
ated coupling reaction (Figure 6). However, the EDC-only 
protocol did not lead to bioconjugation, probably because the 
reaction was carried out at physiological pH and had lower 
efficiency. Addition of NHS increased the coupling efficiency 
by stabilizing the amine-reactive intermediate, allowing the 
reaction to proceed to completion. The EDC/NHS coupling 
protocol showed three bands in the FTIR spectra, represent-
ing amide I features (1,600–1,700 cm−1) from the stretching 
vibrations of the C=O and C–N groups, and amide II features 
between 1,510–1,580 cm−1 from in plane N–H bending as 
well as from C–N stretching vibrations. The slight shift at 
1,707 cm−1 may represent stretching of the carbonyl groups 
of MUA. When compared with FTIR of the unconjugated 
antibody, there was a shift in the amide II band at 1,516 cm−1 
in the unconjugated antibody to 1,569 cm−1 after conjugation, 
as well as formation of a new band at 1,225 cm−1 from an 
amide III linkage.
We demonstrated application of the anti-HER2-QD-
 antibody conjugate for in vitro imaging of fixed and live 
cells. In fixed cell imaging, we found that the QD-antibody 
conjugate attached to the extracellular domain of the HER2 
 receptor, with overall uptake of QDs being significantly higher 
in HER2-overexpressing SK-BR-3 cells (Figure 7A–C) as 
compared with the HER2 under-expressting MCF7 cell line 
(Figure 7D and E). Xiao et al reported that SK-BR-3 cells 
express 15 times higher amounts of HER2 protein and a ten 
times greater number of copies of genes than MCF7 cells, 
making these cells suitable reference materials for HER2 
testing.74 The lower uptake of the QD-antibody probe by 
MCF7 cells may indicate that the QD-antibody probe is 
highly sensitive and detected low amounts of HER2 receptors 
as well. Previous studies have demonstrated a complete out-
line of the cells because the QD-antibody conjugate attaches 
to the extracellular receptors. However, most of these  studies 
used QD-based immunohistochemistry via the primary 
and secondary antibody to localize the HER2  receptors. 
We directly conjugated the antibody to the QD surface, 
and it is likely that because the antibody concentration was 
fairly low, a ring-like outline of cells was only occasionally 
visualized (Figure 7C). We noted that some amount of QD 
aggregation occurred during bioconjugation, and this may 
be due to instability of the MUA coating as small molecular 
thiol ligands may desorb from the QD surface, leading to 
colloidal instability. Further refinement of the procedure 
is therefore required with the use of biocompatible and 
biostable surface coatings. When exposed to live cells, the 
QD-antibody conjugate was rapidly taken up by the SK-BR-3 
cells, as evident from the increased intracellular fluorescence 
(Figure 8A and B) in comparison with MCF7 cells (Figure 8D 
and E). Nuclear staining with diamidino-2-phenylindole 
(DAPI) demonstrated that QDs localized to the perinuclear 
region in live cells exposed to SK-BR-3 (Figure 8C). Our 
results are in agreement with previous studies demonstrat-
ing the molecular pathway of HER2 receptors and indicat-
ing that the HER2 receptor is endocytosed and migrates 
from the cytoplasm to the perinuclear region.75 In a study 
evaluating the molecular mechanisms of movement within 
cells, Watanabe et al demonstrated that, after endocytosis, 
HER2 receptors moved along the membrane by transferring 
actin filaments and were then rapidly transported towards the 
nucleus via microtubules.76
The overall size of the QD-antibody bioconjugate can 
influence its application for cancer localization in vivo. IgG 
is a large antibody of 185 kDa. When conjugated to a QD, 
a larger complex is formed. Smaller antibody fragments would 
increase extravasation into solid tumors in vivo compared 
with larger antibodies.77 The application of small proteins as 
molecular probes for cancer targeting has various advantages, 
including high affinity and specificity, small size, and rapid 
clearance.78 Gao et al showed the application of affibody-
based QD probes for HER2 localization and targeted in vivo 
imaging.79 The main features of affibody molecules are their 
significantly smaller size and molecular weight (7 kDa), high 
affinity, and rapid tumor targeting. Similarly, Barat et al dem-
onstrated the use of small bivalent antibody fragments called 
cys-diabodies for QD bioconjugation and targeted cancer 
localization.80 They conjugated amino-poly(ethylene glycol)-
coated CdTe/ZnS QDs to anti-HER2 cys-diabodies by EMCS 
(N-epsilon-Malemidocaproyl-oxysuccinimide ester) coupling 
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to form an anti-HER2 iQdot. The conjugate showed no spectral 
differences from the unconjugated QDs, and immunofluores-
cence imaging showed homogenous surface labeling of cell 
membranes with the QD conjugate. There was no change in 
the photoluminescence of the QDs after conjugation. They 
demonstrated that cys-diabodies retained the antigen reorga-
nization sites of the antibody and yet had a small size, making 
them more favorable for in vivo imaging applications.
Apart from elucidating the biology, pathology, and evolu-
tion of breast cancer, QD-based molecular probes have been 
investigated for targeted in vivo imaging of cancer.67,70 The 
real challenge in breast cancer therapy is the application 
of bioconjugated QD probes for in vivo targeting of HER2 
receptors as a means for image-guided therapy and cancer 
surgery. Optical imaging is a valuable tool for live imaging 
and particularly tumor targeting using QD probes.81 NIR-QDs 
can be a valuable probe for deep tissue imaging applications. 
This is based on the fact that NIR light can penetrate deep 
tissues without being scattered or absorbed, compared with 
visible light. Hence targeted localization of tumors using 
NIR-QD bioconjugates would allow better resection of tumor 
margins under optical guidance. QDs have been demonstrated 
to be alternative probes for sentinel lymph node localization 
in breast cancer surgery. NIR-QDs would be ideal for this 
application because the NIR fluorescence would be  detectable 
in deep tissues, allowing accurate localization of the senti-
nel lymph node prior to the surgical incision. Based on the 
localization of HER2 receptors in vitro, it is reasonable to 
predict that NIR-QD bioconjugates could potentially be used 
for detecting micrometastasis in the sentinel lymph nodes. 
This may prove invaluable in breast cancer surgery, whereby 
the presence or absence of micrometastasis in the sentinel 
lymph nodes may allow the surgeon to bypass the sentinel 
lymph node biopsy procedure.
The most important step in the clinical translation of this 
QD-based molecular targeting technology is determination of 
its toxicity in vivo. While a considerable amount of research 
has focused on determining the in vitro toxicity of QDs, the 
in vivo behavior of these novel probes needs to be elaborated 
further. Tiwari et al82 reported no significant toxicity of 
QDs conjugated to the anti-HER2 antibody compared with 
unconjugated QDs, indicating that the bioconjugated probes 
were biocompatible and therefore suitable for breast cancer 
imaging and surgery.
Conclusion and future directions
We have demonstrated the bioconjugation of NIR-QDs to an 
anti-HER2 antibody using an EDC/NHS coupling method. 
Addition of NHS increases the efficiency of the coupling 
reaction, leading to a stable QD-antibody  conjugate. HER2 
receptors were successfully localized in both fixed and live 
cancer cells. Given that the NIR-QDs can be visualized in 
deep tissues, this property can be used for image-guided 
delivery of chemotherapeutic agents to cancer sites as well 
as sites of micrometastasis which would otherwise not be 
detected. NIR optical imaging can potentially be used to 
guide the surgeon to an adequate tumor resection margin, 
based on uptake of the NIR-QD antibody probe. While the 
toxicity of the QD-antibody probe is a definite concern, 
active targeting would allow considerably lower doses to 
be used for tumor localization. At the same time, eventual 
resection of the tumor would remove the major bulk of the 
QDs, leading to minimal toxicity. Further studies to inves-
tigate the in vivo behavior of the QD-antibody bioconjugate 
are essential prior to clinical translation.
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